PROCEPT BIOROBOTICS CORP (PRCT) Stock Price & Overview
NASDAQ:PRCT • US74276L1052
The current stock price of PRCT is 26.3225 USD. Today PRCT is down by -5.31%. In the past month the price decreased by -7.18%. In the past year, price decreased by -51.75%.
PRCT Key Statistics
- Market Cap
- 1.484B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.71
- Dividend Yield
- N/A
PRCT Stock Performance
PRCT Stock Chart
PRCT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PRCT. When comparing the yearly performance of all stocks, PRCT is a bad performer in the overall market: 91.53% of all stocks are doing better.
PRCT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRCT. PRCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRCT Earnings
On February 25, 2026 PRCT reported an EPS of -0.53 and a revenue of 76.38M. The company missed EPS expectations (-60.27% surprise) and missed revenue expectations (-20.45% surprise).
PRCT Forecast & Estimates
20 analysts have analysed PRCT and the average price target is 53.81 USD. This implies a price increase of 104.41% is expected in the next year compared to the current price of 26.3225.
For the next year, analysts expect an EPS growth of 15.53% and a revenue growth 22.92% for PRCT
PRCT Groups
Sector & Classification
PRCT Financial Highlights
Over the last trailing twelve months PRCT reported a non-GAAP Earnings per Share(EPS) of -1.71. The EPS increased by 2.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.81% | ||
| ROE | -26.12% | ||
| Debt/Equity | 0.14 |
PRCT Ownership
PRCT Latest News, Press Relases and Analysis
PRCT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19 | 191.579B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.98 | 175.033B | ||
| SYK | STRYKER CORP | 22.48 | 132.327B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.54 | 103.323B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.42 | 49.378B | ||
| IDXX | IDEXX LABORATORIES INC | 38.86 | 47.813B | ||
| BDX | BECTON DICKINSON AND CO | 11.73 | 46.461B | ||
| RMD | RESMED INC | 19.03 | 34.985B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.51 | 33.11B | ||
| DXCM | DEXCOM INC | 26.17 | 25.52B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.02 | 18.338B | ||
| HOLX | HOLOGIC INC | 15.36 | 16.834B | ||
| PODD | INSULET CORP | 36.52 | 16.813B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRCT
Company Profile
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Company Info
IPO: 2021-09-15
PROCEPT BIOROBOTICS CORP
150 Baytech Drive
San Jose CALIFORNIA US
CEO: Reza Zadno
Employees: 756
Phone: 18887167274
PROCEPT BIOROBOTICS CORP / PRCT FAQ
What does PRCT do?
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
What is the current price of PRCT stock?
The current stock price of PRCT is 26.3225 USD. The price decreased by -5.31% in the last trading session.
Does PRCT stock pay dividends?
PRCT does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRCT stock?
PRCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of PROCEPT BIOROBOTICS CORP (PRCT) based on its PE ratio?
PROCEPT BIOROBOTICS CORP (PRCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.71).
Can you provide the growth outlook for PROCEPT BIOROBOTICS CORP?
The Revenue of PROCEPT BIOROBOTICS CORP (PRCT) is expected to grow by 22.92% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of PRCT stock?
PROCEPT BIOROBOTICS CORP (PRCT) has a market capitalization of 1.48B USD. This makes PRCT a Small Cap stock.